Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Polygenic risk scores: how much do they add?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Impact of metabolic dysfunction on cognition in humans

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Apolipoprotein M/sphingosine-1-phosphate: novel effects on lipids, inflammation and kidney biology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Remnant lipoproteins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Relation between plasma and brain lipids

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Elevated apolipoprotein A1 and HDL cholesterol associated with age-related macular degeneration: 2 population cohorts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE OF REVIEW: Current methods to assess genetic risk of familial hypercholesterolemia and coronary artery disease (CAD) focus on testing monogenic mutations in well known genes. Here we review recent developments in polygenic risk scores (PRSs) for LDL cholesterol and for CAD, and how they may add to current risk prediction algorithms.

RECENT FINDINGS: PRSs can identify 10-20 times as many individuals at high polygenic risk compared with monogenic mutations, and PRSs can modulate the effect of a monogenic variant on risk. Current risk factor prediction tools for prevention of CAD incompletely capture polygenic susceptibility, and PRSs may identify subgroups of patients who are likely to benefit more from lipid-lowering therapy. Finally, PRSs can be quantified already at birth, long before other risk factors used to predict CAD, and before clinical manifestations of disease.

SUMMARY: PRSs for CAD may soon be incorporated into clinical practice. Therefore, there is an urgent need to establish both analytical and clinical reporting standards for PRSs, and for validating scores in different ethnicities. Thresholds for intervention need to be established for PRSs and integrated into established risk scores. Training programs are needed for clinical staff to learn to communicate polygenic risk in a comprehensive way to the patient.

OriginalsprogEngelsk
TidsskriftCurrent Opinion in Lipidology
Vol/bind32
Udgave nummer3
Sider (fra-til)157-162
Antal sider6
ISSN0957-9672
DOI
StatusUdgivet - 1 jun. 2021

ID: 65556046